Adhansia Xr is a drug owned by Purdue Pharma Lp. It is protected by 12 US drug patents filed from 2019 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 19, 2038. Details of Adhansia Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10722473 | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(13 years from now) | Active |
| US10500162 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10568841 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10292939 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10111839 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10292938 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10507186 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10512612 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10688060 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US9974752 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10512613 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
| US10449159 | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adhansia Xr's patents.
Latest Legal Activities on Adhansia Xr's Patents
Given below is the list of recent legal activities going on the following patents of Adhansia Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10722473 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Nov, 2023 | US10688060 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jul, 2023 | US10568841 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 May, 2023 | US10507186 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 May, 2023 | US10500162 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 May, 2023 | US10512613 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 May, 2023 | US10512612 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Mar, 2023 | US10449159 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2022 | US10292938 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2022 | US10292939 |
FDA has granted several exclusivities to Adhansia Xr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Adhansia Xr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Adhansia Xr.
Exclusivity Information
Adhansia Xr holds 2 exclusivities. All of its exclusivities have expired in 2024. Details of Adhansia Xr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 27, 2022 |
| M(M-82) | Jun 28, 2024 |
US patents provide insights into the exclusivity only within the United States, but Adhansia Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adhansia Xr's family patents as well as insights into ongoing legal events on those patents.
Adhansia Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adhansia Xr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 19, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adhansia Xr Generic API suppliers:
Methylphenidate Hydrochloride is the generic name for the brand Adhansia Xr. 42 different companies have already filed for the generic of Adhansia Xr, with Specgx Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adhansia Xr's generic
Alternative Brands for Adhansia Xr
Adhansia Xr which is used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD)., has several other brand drugs in the same treatment category and using the same active ingredient (Methylphenidate Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Ironshore Pharms |
| |||
| Rhodes Pharms |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Methylphenidate Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Aytu Biopharma |
| |||
| Commave Therap |
| |||
| Janssen Pharms |
| |||
| Nextwave |
| |||
| Nextwave Pharms |
| |||
| Sandoz |
| |||
| Specgx Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Methylphenidate Hydrochloride, Adhansia Xr's active ingredient. Check the complete list of approved generic manufacturers for Adhansia Xr
About Adhansia Xr
Adhansia Xr is a drug owned by Purdue Pharma Lp. It is used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD). Adhansia Xr uses Methylphenidate Hydrochloride as an active ingredient. Adhansia Xr was launched by Purdue Pharma Lp in 2019.
Approval Date:
Adhansia Xr was approved by FDA for market use on 27 February, 2019.
Active Ingredient:
Adhansia Xr uses Methylphenidate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Methylphenidate Hydrochloride ingredient
Treatment:
Adhansia Xr is used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
Dosage:
Adhansia Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 35MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 45MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 55MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 70MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 85MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 25MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |